The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management

Charles Dwayne Burger, Lesley D'Albini, Susan Raspa, Janis A. Pruett

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Prostacyclins for the treatment of pulmonary arterial hypertension (PAH) have historically been covered under the insurance medical benefit because they require durable medical equipment and are administered by an intravenous, subcutaneous, or inhalation route. However, more treatment options that target the prostacyclin pathway have become available. As the number and type of options expand, an improved understanding of these drugs will aid managed care decision makers in evaluating new treatment options and making clinically sound and cost-effective treatment decisions. PAH is a progressive disease of pulmonary vascular remodeling that increases pulmonary vascular resistance and often results in right-side heart failure and death if left untreated. Adverse event profiles, the complexity of administration modalities, and potential complications must be considered when administering prostacyclin therapy. Traditional modes of administration, with their potential challenges and complications, may have contributed to the unmet need for an oral agent. Another consideration for managed care decision makers is that oral agents are generally covered under the insurance pharmacy benefit. Access to oral medications with long-term outcomes data, as well as the improved convenience of oral therapy, may help patients with PAH maximize function by maintaining a more convenient and consistent therapeutic regimen.

Original languageEnglish (US)
Pages (from-to)S3-S15
JournalThe American journal of managed care
Volume22
Issue number1
StatePublished - Jan 1 2016

Fingerprint

Prostaglandins I
Pulmonary Hypertension
Managed Care Programs
Insurance Benefits
Epoprostenol
Durable Medical Equipment
Therapeutics
Vascular Resistance
Health Care Costs
Inhalation
Lung Diseases
Heart Failure

ASJC Scopus subject areas

  • Health Policy

Cite this

The evolution of prostacyclins in pulmonary arterial hypertension : from classical treatment to modern management. / Burger, Charles Dwayne; D'Albini, Lesley; Raspa, Susan; Pruett, Janis A.

In: The American journal of managed care, Vol. 22, No. 1, 01.01.2016, p. S3-S15.

Research output: Contribution to journalReview article

@article{2ea06110a63c4f629ddb740d87fc8be7,
title = "The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management",
abstract = "Prostacyclins for the treatment of pulmonary arterial hypertension (PAH) have historically been covered under the insurance medical benefit because they require durable medical equipment and are administered by an intravenous, subcutaneous, or inhalation route. However, more treatment options that target the prostacyclin pathway have become available. As the number and type of options expand, an improved understanding of these drugs will aid managed care decision makers in evaluating new treatment options and making clinically sound and cost-effective treatment decisions. PAH is a progressive disease of pulmonary vascular remodeling that increases pulmonary vascular resistance and often results in right-side heart failure and death if left untreated. Adverse event profiles, the complexity of administration modalities, and potential complications must be considered when administering prostacyclin therapy. Traditional modes of administration, with their potential challenges and complications, may have contributed to the unmet need for an oral agent. Another consideration for managed care decision makers is that oral agents are generally covered under the insurance pharmacy benefit. Access to oral medications with long-term outcomes data, as well as the improved convenience of oral therapy, may help patients with PAH maximize function by maintaining a more convenient and consistent therapeutic regimen.",
author = "Burger, {Charles Dwayne} and Lesley D'Albini and Susan Raspa and Pruett, {Janis A.}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "S3--S15",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "1",

}

TY - JOUR

T1 - The evolution of prostacyclins in pulmonary arterial hypertension

T2 - from classical treatment to modern management

AU - Burger, Charles Dwayne

AU - D'Albini, Lesley

AU - Raspa, Susan

AU - Pruett, Janis A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Prostacyclins for the treatment of pulmonary arterial hypertension (PAH) have historically been covered under the insurance medical benefit because they require durable medical equipment and are administered by an intravenous, subcutaneous, or inhalation route. However, more treatment options that target the prostacyclin pathway have become available. As the number and type of options expand, an improved understanding of these drugs will aid managed care decision makers in evaluating new treatment options and making clinically sound and cost-effective treatment decisions. PAH is a progressive disease of pulmonary vascular remodeling that increases pulmonary vascular resistance and often results in right-side heart failure and death if left untreated. Adverse event profiles, the complexity of administration modalities, and potential complications must be considered when administering prostacyclin therapy. Traditional modes of administration, with their potential challenges and complications, may have contributed to the unmet need for an oral agent. Another consideration for managed care decision makers is that oral agents are generally covered under the insurance pharmacy benefit. Access to oral medications with long-term outcomes data, as well as the improved convenience of oral therapy, may help patients with PAH maximize function by maintaining a more convenient and consistent therapeutic regimen.

AB - Prostacyclins for the treatment of pulmonary arterial hypertension (PAH) have historically been covered under the insurance medical benefit because they require durable medical equipment and are administered by an intravenous, subcutaneous, or inhalation route. However, more treatment options that target the prostacyclin pathway have become available. As the number and type of options expand, an improved understanding of these drugs will aid managed care decision makers in evaluating new treatment options and making clinically sound and cost-effective treatment decisions. PAH is a progressive disease of pulmonary vascular remodeling that increases pulmonary vascular resistance and often results in right-side heart failure and death if left untreated. Adverse event profiles, the complexity of administration modalities, and potential complications must be considered when administering prostacyclin therapy. Traditional modes of administration, with their potential challenges and complications, may have contributed to the unmet need for an oral agent. Another consideration for managed care decision makers is that oral agents are generally covered under the insurance pharmacy benefit. Access to oral medications with long-term outcomes data, as well as the improved convenience of oral therapy, may help patients with PAH maximize function by maintaining a more convenient and consistent therapeutic regimen.

UR - http://www.scopus.com/inward/record.url?scp=85019936850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019936850&partnerID=8YFLogxK

M3 - Review article

C2 - 26885569

AN - SCOPUS:85019936850

VL - 22

SP - S3-S15

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 1

ER -